CircRNAs as a novel marker for early warning of adverse cardiac events in the treatment of elderly patients with lung cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900027419

Enrollment

Unknown

Registered

2019-11-12

Start date

2019-12-01

Completion date

Unknown

Last updated

2019-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Interventions

Lung cancer patients with adverse cardiac events, lung cancer patients without adverse cardiac events, non lung cancer patients with adverse cardiac events, non lung cancer patients without adverse ca

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. patients older than 65 years; 2. patients diagnosed with non-small cell lung cancer in hospital; 3. first-line anti-tumor drug treatment.

Exclusion criteria

Exclusion criteria: 1. pregnancy; 2. patients in critical condition who are unable to cooperate and perfect relevant examinations.

Design outcomes

Primary

Measure	Time frame
The positive rate of candidate circRNAs in elderly patients with lung cancer and heart failure;	—

Countries

China

Contacts

Public ContactJingyi Ren

China-Japan Friendship Hospital

renjingyi1213@163.com+86 010-84206809

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026